

REVIEW

Maintaining Intestinal Health: The Genetics and Immunology of Very Early Onset Inflammatory Bowel Disease



Judith R. Kelsen,¹ Robert N. Baldassano,¹ David Artis,² and Gregory F. Sonnenberg²

¹Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; ²Jill Roberts Institute for Research in IBD, Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, and Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, New York

SUMMARY

Very early onset inflammatory bowel disease (VEO-IBD) is a distinct form of IBD. Here, we review the current knowledge of the genetic and immunologic basis of VEO-IBD, which requires further investigation for improved and individualized care.


Inflammatory bowel disease (IBD) is a multifactorial disease caused by dysregulated immune responses to commensal or pathogenic microbes in the intestine, resulting in chronic intestinal inflammation. An emerging population of patients with IBD younger than 5 years of age represent a unique form of disease, termed very early onset IBD (VEO-IBD), which is phenotypically and genetically distinct from older-onset IBD. VEO-IBD is associated with increased disease severity, aggressive progression, and poor responsiveness to most conventional therapies. Further investigation into the causes and pathogenesis of VEO-IBD will help improve treatment strategies and may lead to a better understanding of the mechanisms that are essential to maintain intestinal health or provoke the development of targeted therapeutic strategies to limit intestinal inflammation and promote tissue repair. Here, we discuss the phenotypic nature of VEO-IBD, the recent identification of novel gene variants associated with disease, and functional immunologic studies interrogating the contribution of specific genetic variants to the development of chronic intestinal inflammation. (*Cell Mol Gastroenterol Hepatol* 2015;1:462–476; <http://dx.doi.org/10.1016/j.jcmgh.2015.06.010>)

Keywords: Inflammatory Bowel Disease; Very Early Onset Inflammatory Bowel Disease; Whole Exome Sequencing; Mucosal Immunology.

Inflammatory bowel disease (IBD), comprising Crohn's disease, ulcerative colitis, and indeterminate colitis, is a multigenetic and environmentally triggered disease resulting in a dysregulated immune response to commensal or pathogenic microbes found in the gastrointestinal tract.^{1–7} Patients with IBD exhibit local and systemic immune reactivity to various microbes, have significant alterations in the composition of intestinal commensal bacteria,

and can become colonized with pathogenic or opportunistic bacteria.^{8–15} The multifactorial nature and environmental contribution to IBD is largely responsible for its increased incidence over the last several decades.¹⁶ Added to the complex nature of the disease, host genetics may play a more prominent role in some subpopulations, particularly in very young children (younger than 5 years of age) in whom the disease is termed very early-onset IBD (VEO-IBD).^{17,18} Although this is a heterogeneous population, including some children with mild disease,¹⁹ patients with VEO-IBD can present with a different disease phenotype, including extensive colonic involvement and more severe disease than older children and adults.^{17,20,21} In addition, due to poor response to conventional therapies, severity of inflammation, and greater duration of disease, there are higher rates of morbidity in this population.^{20,22,23} Because of the aggressive disease phenotype, early age of onset, and strong family history of disease, some measure of VEO-IBD is thought to be a monogenic disease, often involving genes associated with primary immunodeficiencies.^{18,20,24} This was elegantly demonstrated with the discovery that several *IL10* (interleukin-10),²⁵ *IL10RA* (interleukin-10 receptor, α), and *IL10RB* (interleukin-10 receptor, β)²³ gene mutations were associated with a phenotype of severe perianal disease and colitis in infants with VEO-IBD. Additional underlying immunodeficiencies or genetic disorders may also present with an intestinal phenotype in

Abbreviations used in this paper: ADAM17, A disintegrin and metalloproteinase domain 17; CGD, chronic granulomatous disease; COL7A1, collagen, type VII, $\alpha 1$; CVID, common variable immunodeficiency; FOXP3, forkhead box protein 3; GUCY2, guanylate cyclase 2; GWAS, genome-wide association studies; IBD, inflammatory bowel disease; IL, interleukin; ILC, innate lymphoid cells; ILC3, group 3 innate lymphoid cells; IgA, immunoglobulin A; IKBKKG, inhibitor of κ light polypeptide gene enhancer in B cells, kinase of, γ ; IPEX, immunodysregulation, polyendocrinopathy, and enteropathy, X-linked; MHCII, major histocompatibility complex class II; NEMO, nuclear factor- κ B essential modulator; RAG, recombination-activating gene; STAT, signal transducer and activator of transcription; TNF, tumor necrosis factor; Treg, regulatory T cell; TTC7A, tetratricopeptide repeat domain-containing protein 7A; VEO-IBD, very early onset inflammatory bowel disease; WASP, Wiskott-Aldrich syndrome protein; WES, whole exome sequencing; XIAP, X-linked inhibitor of apoptosis protein.

 Most current article

© 2015 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2352-345X

<http://dx.doi.org/10.1016/j.jcmgh.2015.06.010>

patients with VEO-IBD.^{20,24} These include, but are not limited to, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome (WAS), immunodysregulation, polyendocrinopathy, and enteropathy, X-linked (IPEX) syndrome, and chronic granulomatous disease (CGD).^{17,20,22,26}

Studying consanguinity and targeted genetic sequencing has been an extremely valuable approach to allow the identification and characterization of genetic variants associated with VEO-IBD. However, these approaches alone may not identify novel and rare gene variants. Recent advances in sequencing technology such as whole exome sequencing (WES) have broadened our understanding of the pathogenesis of VEO-IBD and resulted in further discoveries of genes and pathways associated with the disease.^{26–30} The genomic contribution of IBD has been extensively evaluated through genomewide association studies (GWAS), and over 163 IBD-associated risk loci³¹ have been identified.

Several genes located within the IBD-associated loci are critical for regulation of host defense, involving both the innate and adaptive immune responses toward microbes.³¹ However, GWAS studies have been primarily performed in adult-onset IBD and in children 10 years of age and older, whose disease is most frequently a polygenic complex disease. Furthermore, GWAS often do not capture rare variants, specifically those with a minor allele frequency of <5%. In contrast, a proportion of patients with VEO-IBD have a monogenic-driven disease or multigenic disease enriched with rare variants of the same or interacting immunologic pathways.^{32,23} Thus, as in the case of *IL10RA* and *IL10RB* defects, the development of intestinal inflammation in VEO-IBD patients can be the direct result of defective immune responses.³³

Although WES has revolutionized our ability to study rare variants and to determine the genetic basis of disease, understanding the relevance of the identified variants has remained challenging. The individual patient's phenotype may be shaped by mode of inheritance, epigenetics, and gene-gene interaction. Environmental modifiers such as the intestinal microbiota, antibiotic exposure, infection, or

diet also significantly impact the disease phenotype.^{17,26,32} Because of the clinical presentation, often of severe disease, together with the challenge of identifying the unique pathogenesis of the disease, there is currently no standard of care in the evaluation and treatment for VEO-IBD patients. Identifying the driving forces in patients with particularly severe early-onset disease may lead to group-specific therapeutic approaches. Here we discuss the clinical presentation of VEO-IBD patients, the identification of common gene variants associated with the disease, and functional studies that have demonstrated how these variants may contribute to dysregulated immunologic homeostasis in the intestine.

Clinical Presentation of Very Early Onset Inflammatory Bowel Disease

Pediatric IBD has increased in incidence and prevalence, and this phenomenon has included very young children.^{16,33,34} VEO-IBD remains relatively uncommon, approximately 6% to 15% of the pediatric IBD population is younger than 6 years old, and disease in the first year of life is rare.^{16,34} A subset of patients with VEO-IBD present with a phenotype that is distinct from older children and adults, including extensive colonic disease (pancolitis) in which it is frequently difficult to differentiate ulcerative colitis from Crohn's disease, leading to a diagnosis of indeterminate colitis (Table 1).^{20,34} At diagnosis, patients with VEO-IBD are more commonly diagnosed with ulcerative colitis (35% to 59%) as compared to older onset IBD (children older than 6 years and adults) in which Crohn's disease is more prevalent (55% to 60%). In contrast, approximately 30% to 35% of VEO-IBD patients are diagnosed with Crohn's disease. Indeterminate colitis is also diagnosed more often in patients with VEO (11% to 22%) as compared to older onset IBD (4% to 10%).^{19,35–37}

Although formal guidelines or standards of care do not exist, disease evaluation of this population includes

Table 1. Features of Very Early Onset and Older Onset Inflammatory Bowel Disease

| Feature | VEO-IBD | Older-Onset IBD |
|-------------------------|--|--|
| Disease distribution | Predominately colonic Ileal involvement <20% Extensive disease at presentation | Ileocolonic Less extensive disease at presentation |
| Disease classification | CD: 30%–35% UC: 35%–59% IC: 11%–22% | CD: 55%–60% UC: 40%–45% IC: 4%–10% |
| Positive family history | 40%–50% | 10%–20% |
| Genetic contribution | Increased prevalence monogenic disorders <2 years | Polygenic inheritance |
| Surgical intervention | ~71% | ~55% |
| Other | Therapeutic response to conventional therapy: decreased Consanguinity | |

CD, Crohn's disease; IC, indeterminate colitis; UC, ulcerative colitis.

Table 2. Clinical Presentations and Laboratory Abnormalities of Very Early Onset Inflammatory Bowel Disease Patients

| Type | Gastrointestinal Manifestations | Laboratory Abnormalities | Pathology |
|--|---|--|--|
| B- and T-cell development WAS (WASP) | Microthrombocytopenia Moderate-severe eczema Recurrent or severe infections Colitis: bloody diarrhea | Decreased platelets Low marginal B cells, high transitional B cells, elevated IgA, low IgM Lymphopenia usually present, progressive decline in T cells CD4:CD8 ratio is normal. Natural killer cell abnormalities | Crohn-like inflammatory process: cobblestone appearance and inflammatory pseudo-polyps ³⁸ Ulcerative colitis-like appearance reported: extensive colitis with ulcerations ³⁹ Neutrophil and T _H 2 lymphocyte infiltration |
| Hypogammaglobulinemia, X-linked (BTK) or AR | Diarrhea Chronic infectious diarrhea (<i>Giardia lamblia</i> , <i>Salmonella</i> species, <i>Escherichia coli</i>) Crohn's disease appearance Perirectal abscess and fistula | Hypogammaglobulinemia: defective B-cell maturation secondary to mutations in BTK B cells are severely decreased or absent in the periphery T cells or normal or increased CD4: CD8 ratio is normal or decreased Low IgG, IgA Normal or increased IgM Impaired antibody response Hypogammaglobulinemia ⁴⁰ | Lack of plasma cells in lamina propria |
| Hyper IgM (CD40L, CD40, AICDA, UNG) | Diarrhea, sclerosing cholangitis | Low IgG, IgA Normal or increased IgM Impaired antibody response Hypogammaglobulinemia ⁴⁰ | |
| LRBA deficiency | Abdominal pain, diarrhea Hypoalbuminemia may be present | | Small bowel and colon: acute and chronic inflammation can be seen ⁴¹ |
| Hyper IgE syndrome (STAT3, DOCK8) | Susceptibility to infection (staphylococcal infection) Atopic dermatitis Gastrointestinal manifestations most often secondary to infection | Extremely elevated IgE levels Low IgM Decreased memory B cells Neutropenia can be present T cell lymphopenia | Histology and crypt destruction pattern most resembles infectious agent ^{42,43} |
| Severe combined immunodeficiency (ZAP70, ITK, LCK) | Severe recurrent infection in infancy Chronic diarrhea, malabsorption, and failure to thrive Oral and esophageal candidiasis | B and T cells are decreased in the peripheral blood T cells may have immature phenotype Variants of severe combined immunodeficiency can have less severe lymphopenia B cells (CD19-HLA-DR) may be normal or decreased | Hypocellular lamina propria lacking plasma cells or lymphocytes Graft versus host disease-like process in colon or small bowel can be present |
| X-linked severe combined immunodeficiency (<i>IL2RG</i>) | Same | Defective IgG, IgA, normal IgM Neutropenia Absence of T cells and natural killer cells Normal B cells | Same |
| Omenn syndrome (RAG1, RAG2, Artemis, IL7Ra, LIG4, ADA, CHD7) | Diffuse erythroderma Hepatosplenomegaly Lymphadenopathy Chronic diarrhea Failure to thrive | Hypereosinophilia and increased IgE Can have oligoclonal T cells ⁴⁴ and reduced B cells ⁴⁵ | Graft versus host disease: numerous apoptotic crypts cells in colon Increase in lamina propria eosinophils ⁴⁶ |

Table 2. Continued

| Type | Gastrointestinal Manifestations | Laboratory Abnormalities | Pathology |
|--|---|--|---|
| Common variable immunodeficiency (TAC1, ICOS, CD19, CD20, CD21, CD81) | Heterogeneous presentation Recurrent bacterial infection Chronic infectious diarrhea <i>Helicobacter pylori</i> infection common: atrophic gastritis and pernicious anemia ⁴⁸ Malabsorption ⁴⁸ Granulomatous enteropathy | Decreased memory B cells Defective plasma C (CD27 ⁺ , CD19, HLA-DR) T cells (CD2, CD3) usually quantitatively normal, T cell abnormalities common CD4:CD8 can be normal or decreased ⁴⁹ | Antrum: nonspecific increase in lamina propria lymphocytes; apoptotic cells ⁴⁷ <i>Helicobacter pylori</i> positive: atrophic gastritis Small intestine: villous atrophy, increased epithelial lymphocytosis ⁴⁷ Plasma cells absent or decreased ⁵⁰ |
| Epithelial defects | | | |
| ADAM 17 deficiency | Present in neonatal period with watery diarrhea that progresses to bloody diarrhea | | Hypoplastic crypts in small bowel |
| Familial diarrhea (GUCY2C) | Neonatal onset of watery diarrhea | Neonatal electrolyte disturbances | Crohn's disease-like appearance |
| X-linked ectodermal dysplasia and immunodeficiency (IKBKG) | Diarrhea, failure to thrive | B-cell activation defects, can have hypogammaglobulinemia | Enterocolitis with villous atrophy and epithelial shedding ⁵¹ |
| TTC7A deficiency | Severe diarrhea | Natural killer cell abnormalities | Small bowel: villous atrophy |
| Kindler syndrome (FERMT1) | Colitis presentation | Can have low immunoglobulin levels | Colon: apoptosis |
| | Blistering skin defects and hyperkeratosis of palms and soles | Defect in vaccine response | Intestinal epithelium: focal detachment of epithelium |
| | | Can have eosinophilia | Ulcerations |
| Dystrophic epidermolysis bullosa (COL7A1) | Bloody diarrhea | | Colon: apoptosis Severe colitis |
| Phagocyte defects | | | |
| Chronic granulomatous disease (CYBB: x-linked, CYBA, NCF1, NCF2, NCF4, RAC1) | Recurrent infection/abscesses Perianal disease/fistula Esophageal and gastric outlet obstruction Colitis | Abnormal respiratory burst | Transmural and discontinuous inflammation, with aphthous or serpiginous ulcers can be seen, can be indistinguishable from Crohn's disease ⁵² Intestinal granulomas, increased compared to Crohn's disease Crohn's disease-like lesions in the small bowel Fistulas, longitudinal ulcers, stenosis Ulcerative colitis appearance Pigmented macrophages Perianal disease and oral manifestations may appear Colonic disease, adhesions, and strictures may be present |
| Glycogen storage disease type 1 (SLC37A4) | Crohn's disease presentation | Neutropenia | |
| Leukocyte-adhesion deficiency (ITGB2) | Perianal disease and oral manifestations | Neutrophil dysfunction | |
| | Defective chemotaxis, phagocytosis, and bacterial killing | Increased peripheral granulocytes | |
| | Abnormal respiratory burst | | |
| Genetic variants in the IL-10/IL-10R pathway and regulatory T cells | | | |
| IL-10 ligand and IL10RA and IL10RB | Most frequently neonatal onset of disease, bloody diarrhea Perianal fistula Arthritis Abscesses | Abnormal phosphorylation of STAT3 mediated by IL-10 | Ileal and colonic inflammation, ulcerations, inflammatory infiltrates |

Table 2. Continued

| Type | Gastrointestinal Manifestations | Laboratory Abnormalities | Pathology |
|---|--|---|---|
| X-linked immune dysregulation, polyendocrinopathy, enteropathy (FOXP3, STAT1) | Polyendocrinopathy Recurrent infection Severe enteropathy with watery diarrhea, can be bloody | Lack of CD4 ⁺ , CD25 ⁺ , FOXP3 ⁺ regulatory T cells Elevated IgA and IgE Normal B cell numbers Eosinophilia | Extensive villous atrophy Features of graft versus host disease with apoptosis of epithelial cells Presence of antienterocyte antibodies along brush border of duodenum ⁵³ Lymphocytic, neutrophilic and eosinophilic infiltration of crypts and crypt abscesses ⁵³ Colitis |
| Hyperimmune or autoinflammatory Mevalonate kinase deficiency (MVK) | Diarrhea Abdominal pain, emesis Recurrent fevers | Hyperimmunoglobulinemia D Natural killer cell dysfunction Elevation of inflammatory markers erythrocyte sedimentation rate, C-reactive protein | Colon: ulcers, cellular infiltrate, apoptosis ⁵⁴ |
| Familial Mediterranean fever (MEFV) | Recurrent fevers, diarrhea Abdominal pain Joint pain Amyloidosis Vasculitis Peritonitis Recurrent oral aphthae | Elevated white blood cell count and inflammatory markers | Small bowel inflammation ⁵⁵ Changes similar to Crohn's disease with chronic inflammation and ulceration may appear ⁵⁶ |
| X-linked lymphoproliferative syndrome 1 (XLP1) (SH2D1A), defective SLAM | Epstein-Barr virus triggered hemophagocytic lymphohistiocytosis | Hypogammaglobulinemia Poor antibody response | Unspecified colitis, may have absent plasma cells |
| X-linked lymphoproliferative syndrome 2 (XLP2, XIAP) | Epstein-Barr virus triggered hemophagocytic lymphohistiocytosis Clinical features similar to observed in Crohn's disease | Hypogammaglobulinemia Decreased natural killer cells can be present | Features similar to Crohn's disease Apoptosis can be seen |
| Hermansky-Pudlak syndrome (IBD phenotype involvement: HPS1, HSP4, HSP6) | Oculocutaneous albinism Easy bruising Inflammatory bowel disease symptoms of abdominal pain, diarrhea, bloody can be present | Normal platelet count Prolonged bleeding time Platelet dysfunction | Broad ulcers Brown granular pigmentation Nonnecrotizing granulomas |

laboratory, radiologic, and endoscopic evaluation (Table 2). A diagnosis at a very young age should trigger concern for a monogenic-driven disease, particularly in IBD diagnosed when the patient is younger than 2 years of age. Furthermore, extensive family history, including a history of disease in male family members (such as in X-linked disease) or a history of infection, skin disease, or autoimmunity can help guide the appropriate laboratory screening. The laboratory studies should include not only the routine screening used for IBD diagnosis but also an immunologic evaluation. This includes vaccine titers, immunoglobulin profiles, analyses of B- and T-cell function, and a dihydro-rhodamine flow cytometry assay, and if necessary more targeted phenotyping and functional profiling of the systemic and mucosal immune system. As shown in Table 2, these studies may point to an underlying defect such as neutropenia, which may represent a monogenic disorder causing functional defects in neutrophils such as glycogen storage disease type 1b, leucocyte adhesion deficiency, or congenital neutropenia.

Genetic Variants Associated With VEO-IBD and Their Immunologic Consequences

Monogenic diseases that can present with the phenotype of intestinal inflammation include those that cause defects of intestinal epithelial barrier function, phagocyte bacterial killing, development and function of the adaptive immune system, and hyper- or autoimmune-inflammatory disorders.³² These genetic alterations may differentially influence the development and progression of intestinal inflammation, so these patients will likely exhibit significant heterogeneity in their responsiveness to therapeutic interventions. We will discuss what we have learned from mouse models and translational patient-based studies, which should be considered when developing therapeutic strategies for these unique patient populations.

Genetic Variants Influencing Intestinal Epithelial Barrier Function

Mutations in genes associated with maintaining integrity of the intestinal epithelial barrier can present with intestinal inflammation in patients with VEO-IBD. These include loss-of-function mutations in *ADAM17* (A disintegrin and metalloproteinase domain 17) resulting in *ADAM17* deficiency,^{57,58} in *IKBKG* (inhibitor of κ light polypeptide gene enhancer in B cells, kinase of, γ ; encoding nuclear factor- κ B essential modulator: NEMO) resulting in X-linked ectodermal dysplasia and immunodeficiency,⁵⁹ in *COL7A1* (collagen, type VII, α 1) resulting in dystrophic epidermolysis bullosa,⁶⁰ *FERMT1* (Fermitin family homolog 1) resulting in Kindler syndrome,^{61–63} and *TTC7A* (tetrapeptide repeat domain-containing protein 7A,²⁹ or gain-of-function mutations in *GUCY2* (guanylate cyclase 2) resulting in familial diarrhea.^{17,64} Mutations in these genes may all lead to an impairment of the intestinal epithelial barrier through distinct pathways, such as limiting epithelial

regeneration (*ADAM17*),⁶⁵ loss of signaling pathways involved in gene expression (*IKBKG*),^{66,67} altered cell adhesion, barrier formation, apoptosis (*COL7A1*, *FEMT1*, and *TTC7A*),^{29,60–63} or impaired bacterial sensing and ion homeostasis (*GUCY2*).^{17,64} The intestinal histology of patients with epithelial defects can be helpful in distinguishing the disease from other causes of intestinal inflammation. For example, patients with *IKBKG* (NEMO) defects may have villous atrophy or epithelial cell shedding on pathologic examination.⁶⁸ In contrast, histology in patients with *ADAM17* mutations may demonstrate hypoplastic crypts in the small bowel secondary to a low rate of epithelial production, as *ADAM17* is necessary for transforming growth factor- α to be cleaved from the cell membrane.^{69,70}

The intestinal barrier is necessary to maintain a physical separation between commensal bacteria and the mammalian immune system, and a breakdown in this barrier through multiple distinct pathways can directly promote chronic intestinal inflammation.^{1,3} In addition to the genes we have listed, intestinal barrier function is maintained through a number of physical and biochemical structures, including mucus production, intestinal epithelial cell tight junction proteins, immunoglobulin A (IgA), and antimicrobial peptides (Figure 1). In mice, chemical disruption of the intestinal barrier through administration of dextran sodium sulfate in drinking water results in dissemination of commensal bacteria and activation of the innate immune system.⁷¹ Chronic exposure to dextran sodium sulfate can lead to activation of the adaptive immune system and to the development of proinflammatory, commensal bacteria-specific B- and T-cell responses,^{8,72} which are similar to those observed in IBD patients.^{8,73}

Intestinal epithelial cells play an important role in directly regulating immunologic homeostasis in the intestine, as mice with intestinal epithelial cell lineage-specific deletion of factors regulating the nuclear factor- κ B pathway, including NEMO and *I κ B kinase- β* , have an increased susceptibility to develop chronic intestinal inflammation.^{66,67} Although we know that loss of intestinal barrier function can directly cause intestinal inflammation, additional mouse models and translational patient-based approaches are required to further define how mutations in these genes specifically lead to a breakdown in the barrier, and whether we can develop more targeted therapies to restore barrier integrity and limit chronic inflammation.

Genetic Variants Impairing Development of the Adaptive Immune System

Several genetic variants can alter the development or function of adaptive immune cells in a cell intrinsic or extrinsic manner.³² Defects that affect development or function of B cells and T cells occur with loss-of-function mutations in recombination-activating genes (*RAG1* or *RAG2*) or the IL-7R (*IL7R*) causing Omenn syndrome, or the *PTEN* (phosphatase and tensin homolog) gene causing PTEN syndrome. Defects in *RAG1*, *RAG2*, or *IL-7R* can cause cell-intrinsic defects in the development of both T cells and B cells by blocking either early lymphocyte survival or




Figure 1. Intestinal epithelial barrier function plays an essential role in maintaining intestinal health. Physical and biochemical barriers, including tight junctions, immunoglobulin A, antimicrobial peptides, mucus, and the ILC3-IL-22 pathway, maintain intestinal epithelial barrier function. This is essential to maintain anatomic segregation between commensal bacteria and the mammalian immune system. Loss of this physical segregation can promote dysregulated innate and adaptive immune cell responses. Identified genetic variants that result in a loss or gain of function mutation and are associated with very early onset inflammatory bowel disease are noted in orange boxes.

recombination of the B-cell receptor or T-cell receptor.^{74–76} Defects in B-cell development lead to an absence of circulating mature B cells and antibody production, which have been linked to an IBD phenotype.⁷⁷ This includes agammaglobulinemia, which can also occur in X-linked agammaglobulinemia⁷⁸ and CVID, a complex and heterogeneous disease, with the responsible mutations known for only a minority of cases.⁷⁹ Recently, one candidate gene causing CVID and potentially contributing to intestinal inflammation was identified using WES as a loss-of-function mutation in *LRBA* (lipopolysaccharide-responsive beige-like anchor), resulting in multiple defects in immune cell populations.⁴⁰

Related to CVID, antibody deficiencies associated with IBD manifestations include IgA deficiency and severe combined immunodeficiency, which can be secondary to multiple variants that influence the development or function of the adaptive immune system (including *RAG1*, *RAG2*, *JAK3*, *CD45*, *CD3G*, *ZAP70*, *ADA*, *DCLRE1C*).^{32,77,80} Omenn syndrome, a recessive form of severe combined immunodeficiency, involves abnormal development of B cells and T cells, and can also be associated with intestinal disease as well as severe eczematous rash.^{80,81} In these patients, laboratory studies indicate increased oligoclonal T cells and reduced B cells, and histologic examination can show an intestinal graft versus host appearance.^{82,83} Conversely, overproduction of specific immunoglobulins, such as hyper IgM, hyper IgE syndrome (resulting from a loss of function mutation in *DOCK8*) can also result in intestinal inflammation and an IBD phenotype.⁸⁴

It is currently unclear exactly how these selective impairments of the adaptive immune system can manifest in intestinal inflammation. There is a potential involvement of altered regulatory pathways or chronic infections with pathogenic and opportunistic microbes. Therefore, additional lines of study are required to further interrogate the link of these mutations to intestinal inflammation.

Wiskott-Aldrich syndrome results from a loss-of-function mutation in the Wiskott-Aldrich syndrome protein (*WASP*), and patients can exhibit thrombocytopenia, eczema, immune deficiencies, and intestinal inflammation.⁸⁵ The clinical manifestation of VEO-IBD patients with this genetic defect can be pancolitis in addition to other autoimmune processes. *WASP* is a critical cytoskeleton protein expressed in hematopoietic cells, and it is required for the normal development and function of multiple cell types.^{86,87} *WASP* is critical for peripheral B-cell development and function and thus the ability to respond to antigens.^{88,89} Laboratory studies in these patients may show thrombocytopenia, low IgM levels, low marginal B cells, and lymphopenia.⁹⁰ Nguyen et al⁹¹ identified that intestinal inflammation in *WASP*-deficient mice was critically dependent upon inflammatory T cells, which may result from impaired development of regulatory T cells (Tregs) in the thymus and periphery.⁹² Surprisingly, these defects are likely occurring in a cell-extrinsic manner, as the absence of *WASP* in cells of the innate immune system directly contributed to the development of inflammatory T-cell responses in mice.⁹³

The causes of intestinal inflammation in other similar patient populations are less well understood, but defects in regulatory T cells, IgA, and abnormal selection of T-cell and B-cell specificities likely contribute. Additional immunologic analyses and mouse models, such as those we have described, are needed to define the causes of disease further and to develop potential therapeutic options in these patient populations.

Genetic Variants Impairing Regulatory T Cells

Defects in regulatory T cells can clinically present as colonic disease as well as an enteropathy. IPEX syndrome is most often secondary to mutations of the forkhead box protein 3 (*FOXP3*) gene, a transcription factor that is essential for the development and immunosuppressive

activity of CD4 Foxp3⁺ Tregs.^{94,95} There are over 20 mutations in *FOXP3* that have been identified in patients with IPEX,⁹⁶ and patients frequently present with neonatal severe secretory diarrhea, failure to thrive, infection (due to defects in immunoregulation), skin rash, insulin-dependent diabetes, thyroiditis, cytopenias, and other autoimmune disorders.^{94,95} Tregs are absent or dysfunctional in these patients, and in the intestine histologic analyses may reveal infiltration of inflammatory cells in the lamina propria and submucosa of the small bowel and colon as well as changes in the mucosa of the small bowel.⁹⁴ Other genetic defects have been found to cause IPEX-like disease, including loss-of-function mutations impacting IL-2/IL-2R interactions, *STAT5b* (signal transducer and activator of transcription 5b), and *ITCH* (itchy E3 ubiquitin protein ligase), or gain-of-function mutations in *STAT1*, all of which critically influence the development and function of Tregs.⁸¹ Further, Zeissig et al⁹⁷ have recently identified in VEO-IBD a novel loss of function mutation in *CTLA4* (cytotoxic T lymphocyte-associated protein 4), a surface molecule of regulatory T cells that directly suppresses effector T-cell populations.

The mechanisms by which regulatory T cells limit intestinal inflammation are well characterized in mice. Tregs

can develop in the thymus as “natural Tregs” and directly contribute to limiting proinflammatory T cells in the intestine.⁹⁸ The composition of commensal bacteria influences the repertoire of Tregs,⁹⁸ and commensal bacteria-specific “induced Tregs” can also be generated in the periphery after sampling of commensal bacteria by dendritic cells in the intestine and migration to the mesenteric lymph node (Figure 2).^{1,5,99,100} Once generated, Tregs can then promote intestinal homeostasis through direct regulation of innate and adaptive immune cell responses to commensal bacteria, a process that involves cytokine production, direct cell-cell contact (in part through CTLA4), and sequestering of growth factors.^{1,5,99}

Consistent with a major role for Tregs in limiting proinflammatory immune cell responses to commensal bacteria, mice deficient in IL-2 or FoxP3 develop significantly less intestinal inflammation when maintained in germ-free versus conventional housing conditions, but they exhibit comparable levels of systemic autoimmunity.^{101,102} Recent evidence also suggests that the balance of tissue-specific IL-23 and IL-33 expression in mice is critical for regulating the function of Tregs in the intestine and chronic inflammation,¹⁰³ although the role of these pathways in human VEO-IBD has not been examined.




Figure 2. Regulatory T cells, interleukin-10 (IL-10) and ILC3 critically limit dysregulated immune responses to commensal bacteria. Regulatory T cells (Treg) can differentiate in the thymus or periphery and limit immune cell responses to intestinal commensal bacteria through multiple mechanisms, including cytokine production, direct cell-to-cell contact and sequestering of growth factors. Further, IL-10 production by multiple cell types can directly promote anti-inflammatory responses from myeloid cells to limit intestinal inflammation. ILC3 can also directly limit proinflammatory T cells through MHCII-dependent interactions. iTreg, inducible regulatory T cell; nTreg, natural regulatory T cell. Identified genetic variants that result in a loss or gain of function mutation and are associated with very early onset inflammatory bowel disease are noted in orange boxes.

Genetic Variants in the Interleukin-10/Interleukin-10 Receptor Pathway and Related Cytokine Family Members

Homozygous loss of function mutations in *IL10* ligand and receptors *IL10RA* and *IL10RB* are associated with significant intestinal inflammation, particularly in neonatal or infantile VEO-IBD, with a phenotype of severe enterocolitis and perianal disease.^{23,25} In addition, compound heterozygote loss of function mutations of *IL10RA* have been reported with neonatal Crohn's disease and enterocolitis.¹⁰⁴ IL-10 is an anti-inflammatory cytokine secreted by a variety of cells, including dendritic cells, natural killer (NK) cells, eosinophils, mast cells, macrophages, B cells and CD4⁺ T cell subsets (including T_H2 cells, T_H1 cells, T_H17 cells and Treg).^{105,106} IL-10 maintains homeostasis through suppression of an excessive proinflammatory response and exerts its effect through binding to the IL-10 receptor, IL-10R, which is a tetrameric complex.¹⁰⁷ It is composed of 2 distinct chains, 2 molecules of IL-10R1 (α chain) and 2 molecules of IL-10R2 (β chain).¹⁰⁸ IL-10 binding to IL-10R activates the JAK1/STAT3 cascade, which subsequently limits proinflammatory gene expression.¹⁰⁸ In addition to intestinal inflammation, IL-10 defects are associated with arthritis, folliculitis, and a predisposition to lymphoma.^{104,109} Given that the defects in IL-10-IL-10R interactions predominantly influence the immune system, a potential treatment for these patients is successful hematopoietic stem cell transplantation.¹¹⁰ Although this can be challenging and typically requires an HLA-identical donor, there has been recent success reported with haploidentical stem cell transplantation, however nonengraftment complications can occur.¹¹¹

An essential role for IL-10 in limiting intestinal inflammation was demonstrated when IL-10 deficient mice were generated and found develop severe spontaneous colitis,¹¹² and subsequent studies by Sartor et al¹¹³ identified that the intestinal inflammation in IL-10-deficient mice was entirely dependent upon the presence of commensal bacteria. Therefore, IL-10 plays a critical role in limiting dysregulated immune cell responses to intestinal commensal bacteria (Figure 2). The exact cellular sources and targets of IL-10 that contribute to the maintenance of intestinal homeostasis have been less well defined until the recent development of mice that permit conditional deletion of IL-10 and IL-10R. These critical studies have revealed an essential role of regulatory T cell-intrinsic IL-10 expression in preventing intestinal inflammation in mice.^{114,115} Further, it was recently demonstrated that IL-10R expression on myeloid cells in mice is critical to elicit anti-inflammatory responses and limit T cell-dependent intestinal inflammation.^{116,117} Critically, patients with loss-of-function mutations in *IL10RA* or *IL10RB* also exhibited an impaired ability to differentiate anti-inflammatory myeloid cells in vitro, and rather exhibited increased proinflammatory properties, such as elevated expression of IL-6, IL-12, tumor necrosis factor- α (TNF α), MHCII (major histocompatibility complex class II), and costimulatory molecules.¹¹⁶ Although mouse models have provided invaluable insight into human health

and disease, it should be noted that mice deficient in IL10 do not completely replicate the phenotypes of humans with loss-of-function mutations in IL10, likely due to many confounding factors.

IL-22 is a cytokine that is related to IL-10, shares the IL-10R2 chain with a unique IL-22R1, signals through predominantly STAT3, and also plays a critical role in mediating intestinal homeostasis.¹¹⁸ However, unlike IL-10, the functional IL-22R is restricted to predominantly non-hematopoietic cells; in the intestine, IL-22 acts almost exclusively on intestinal epithelial cells to mediate innate immunity and intestinal barrier function (Figure 1).¹¹⁸ IL-22 can be produced by T_H17 cells, and more recently has been identified to be predominantly expressed by a previously unrecognized cell type of the innate immune system, termed group 3 innate lymphoid cells (ILC3).^{118,119} This breakthrough in immunology has led to the identification of other members of the innate lymphoid cell (ILC) family, including group 1 ILCs that express T-bet and proinflammatory cytokines TNF α and interferon- γ , and group 2 ILCs that express GATA3 and type 2 cytokines IL-4, IL-5, IL-9, IL-13, and amphiregulin.^{119,120}

The ILC family exhibits a heterogeneity comparable to that of differentiated CD4 T-cell subsets, and plays a profound role in regulating intestinal health and disease in mouse models.¹¹⁸⁻¹²⁰ Critically, recent reports suggest that ILC3 is a dominant source of IL-22 in the intestine of healthy humans, and that dysregulated ILC responses are observed in adult patients with IBD.¹²¹⁻¹²⁷ Further, we have also recently identified that ILC3 expresses MHCII, and that selective deletion of MHCII on ILC3 results in dysregulated CD4 T-cell responses and spontaneous intestinal inflammation.¹²² MHCII⁺ ILC3 selectively induces cell death of proinflammatory, commensal bacteria-specific CD4 T cells in the intestine; critically, we observed that MHCII was reduced on ILC3 from intestinal biopsy tissues of pediatric IBD patients versus non-IBD controls, and that this was inversely correlated with the level of proinflammatory T_H17 cells.¹²⁸

Despite these advances, ILC and IL-22 responses have yet to be explored in VEO-IBD. Given the importance of these pathways in mediating intestinal health and disease, it is likely that the genetic variations associated with VEO-IBD, such as IL7/IL7R, may differentially influence ILC responses.

Genetic Variants Influencing Bacterial Recognition and Clearance

Chronic granulomatous disease (CGD) is a result of defective intestinal phagocytes, specifically the granulocytes responsible for bacterial killing and clearance.¹²⁹ The NADPH oxidase complex is responsible for killing ingested microbes through its production of the respiratory burst. Mutations in any part of the complex molecules (CYBB, CYBA, NCF1, NCF2, NCF4) can result in intestinal inflammation as well as autoimmune disease.^{130,131} Intestinal inflammation can be observed in as many as 40% of patients with CGD.^{52,132-134}

Several variants have been associated with VEO-IBD, in particular defective NCF2 (neutrophil cytosolic factor 2)

results in altered binding to RAC2 (ras-related C3 botulinum toxin substrate 2).¹³⁵ These patients can present in the neonatal or first year of life with colitis, severe fistulizing perianal disease, and stricturing.¹³⁵ Histology frequently demonstrates multiple granulomas that may not have associated inflammatory change.²⁶ Critically, a recent study by Dhillon et al¹³⁶ identified that heterozygous loss-of-function mutations in components of the NADPH oxidase complex can determine susceptibility to VEO-IBD, without directly causing overt immunodeficiency. Other neutrophil defects that are associated with VEO-IBD include leukocyte-adhesion defect due to mutation in ITGB2 (integrin, β 2).^{137,138} These patients can present with an IBD phenotype, history of bacterial infection, and laboratory studies remarkable for increased peripheral granulocytes.¹³⁹ Glycogen storage disease type 1b, with hallmark features of neutropenia and neutrophil granulocyte dysfunction, can present with intestinal inflammation.¹⁴⁰

The reasons why CGD and other bacterial processing defects may manifest in intestinal inflammation are poorly understood and warrant additional research. It is possible that the causes include bacterial overgrowth or dysbiosis in the intestine, dysregulated activation of the innate and adaptive immune system, or both.

Further, the therapies used to treat such patients need to be carefully considered. For example, anti-TNF α therapy is contraindicated in CGD; although it is effective for intestinal disease, it can increase the risk of severe infections in these patients.¹⁴¹ Other therapies include leukine, antibiotics, and allogeneic hematopoietic stem cell transplantation, which have demonstrated some success.¹⁴² Recent evidence suggests that IL-1R antagonists may be a particularly attractive approach to limit disease in mouse models and patients with CGD by restoring autophagy and directly limiting inflammation.¹⁴³

Hyper- and Autoimmune-Disorders

Several autoimmune diseases have been linked with intestinal inflammation in children with VEO-IBD. These include mevalonate-kinase deficiency,¹⁴⁴ familial Mediterranean fever (FMF),^{145,146} Hermansky-Pudlak syndrome,¹⁴⁷ and X-linked lymphoproliferative syndrome (types 1 and 2).^{28,148,149} These diseases occur due to loss-of-function mutations in an enzyme critical for metabolism (mevalonate-kinase deficiency), cytoskeletal proteins (familial Mediterranean fever), proteins involved in organelle fusion or biogenesis (Hermansky-Pudlak syndrome), or proteins involved in cell signaling or apoptosis (X-linked lymphoproliferative syndrome). Although there are many additional clinical manifestations in these patients, 20% of patients with X-linked lymphoproliferative syndrome that have a loss-of-function defect in the gene X-linked inhibitor of apoptosis protein (*XIAP*), present with VEO-IBD.¹⁵⁰

XIAP is involved in nucleotide-binding oligomerization domain-containing protein 2 (NOD2)-mediated nuclear factor- κ B signaling, so these children may have an impaired ability to sense bacteria. In addition, as an inhibitor of apoptosis, it prevents apoptosis of activated T cells, thus

allowing for expansion and survival of T cells in response to pathogens.^{151,152} Therefore, in *XIAP* deficiency, due to the inability to clear pathogens, there is a hyperinflammatory state with increased production of cytokines resulting in an IBD phenotype.^{150,152} Children with these mutations can present with severe colonic and perianal fistulizing disease,^{28,153} of great concern, Epstein-Barr virus infection can result in fatal hemophagocytic lymphohistiocytosis.¹⁵³

This was not an exhaustive description of the rare genomic drivers of VEO-IBD, but it highlights the different components of the immune system, including innate and adaptive responses, involved in this disease. Treatments guided toward the specific defect, such as IL-1 antagonists, colchicine, hematopoietic stem-cell transplantation, or leukine can be used if the defect is determined. Additionally, monitoring for potential complications associated with a genetic defect is essential, such as in *XIAP*, IL-10 gene variants, and CGD. In addition to these monogenic diseases, VEO-IBD has been shown to have a high degree of genetic heterogeneity. It is therefore likely that there are more pathways involved in VEO-IBD, and the outcome of therapeutic intervention can be improved through further study and identification of the associated variants. Using next-generation sequencing technology such as WES can improve the detection of variants and the diagnosis of disease. Further, there is an urgent need to also directly translate genes to function and to functionally profile the immunologic significance of known genetic variations in intestinal inflammation.

Perspective and Future Directions in Genetic and Immunologic Analyses of Very Early Onset Inflammatory Bowel Disease

To advance our understanding of VEO-IBD, new sequencing technology must be used to completely survey the genetic landscape of this disease. Immunologic studies spanning basic mouse models and translational patient-based approaches are required to determine the contribution of those genetic variations to human disease. Given that dysregulated interactions between the immune system and commensal bacteria underlie the pathogenesis of intestinal inflammation, it is also important to include analyses of the composition and function of the microbiome. Given that these patient populations are studied worldwide and sometimes in small numbers, an international registry containing the genetic, immunologic, and environmental data of VEO-IBD patients could prove beneficial in our goal of better understanding the effects of different variants within known genes and identifying new gene defects that cause IBD through the study of mutations that arise in the same genes of multiple unrelated individuals. With an increased understanding of the disease processes operating in VEO-IBD, we can begin to individualize therapies to the specific patient or patient groups, as well as employ unconventional therapies that are not routinely part of the IBD therapeutic arsenal. These approaches could provide a

roadmap to establishing a standard of care for this disease and improving patient quality of life.

References

1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature* 2011; 474:298–306.
2. Maynard CL, Elson CO, Hatton RD, et al. Reciprocal interactions of the intestinal microbiota and immune system. *Nature* 2012;489:231–241.
3. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol* 2010;10:159–169.
4. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science* 2012;336:1268–1273.
5. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell* 2014;157:121–141.
6. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; 474:307–317.
7. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med* 2009;361:2066–2078.
8. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest* 2004; 113:1296–1306.
9. Baumgart M, Dogan B, Rishniw M, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive *Escherichia coli* of novel phylogeny relative to depletion of clostridiales in Crohn's disease involving the ileum. *ISME J* 2007;1:403–418.
10. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. *Gastroenterology* 2004;127:412–421.
11. Dalwadi H, Wei B, Kronenberg M, et al. The Crohn's disease-associated bacterial protein I2 is a novel enteric T cell superantigen. *Immunity* 2001;15:149–158.
12. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. *BMC Microbiol* 2011;11:7.
13. Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. *Inflamm Bowel Dis* 2009;15:653–660.
14. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology* 2010; 139:1844–1854.e1.
15. Martin HM, Campbell BJ, Hart CA, et al. Enhanced *Escherichia coli* adherence and invasion in Crohn's disease and colon cancer. *Gastroenterology* 2004; 127:80–93.
16. Benchimol EI, Guttman A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. *Gut* 2009;58:1490–1497.
17. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. *Gut* 2013;62:1795–1805.
18. de Ridder L, Weersma RK, Dijkstra G, et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. *Inflamm Bowel Dis* 2007;13:1083–1092.
19. Benchimol EI, Mack DR, Nguyen GC, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. *Gastroenterology* 2014; 147:803–813.e7.
20. Glocker E, Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency? *Cell Mol Life Sci* 2012; 69:41–48.
21. Ruemmele FM, El Khoury MG, Talbotec C, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. *J Pediatr Gastroenterol Nutr* 2006;43:603–609.
22. Cannioto Z, Berti I, Martellosi S, et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. *Eur J Pediatr* 2009;168:149–155.
23. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med* 2009;361:2033–2045.
24. Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. *Inflamm Bowel Dis* 2007;13:1430–1438.
25. Glocker EO, Frede N, Perro M, et al. Infant colitis—it's in the genes. *Lancet* 2010;376:1272.
26. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. *Clin Gastroenterol Hepatol* 2013;11:1050–1063.
27. Mao H, Yang W, Lee PP, et al. Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease. *Genes Immun* 2012;13:437–442.
28. Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. *Genet Med* 2011;13:255–262.
29. Avitzur Y, Guo C, Mastropaolo LA, et al. Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. *Gastroenterology* 2014;146:1028–1039.
30. Kammermeier J, Drury S, James CT, et al. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease—evaluation and prospective analysis. *J Med Genet* 2014;51:748–755.
31. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012;491:119–124.
32. Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. *Nat Rev Immunol* 2013;13:519–533.
33. Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. *Gastroenterology* 2012;143:285–288.
34. Uhlig HH, Schwerdt T, Koletzko S, et al. The diagnostic approach to monogenic very early onset

- inflammatory bowel disease. *Gastroenterology* 2014; 147:990–1007.e3.
35. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. *J Pediatr* 2005; 146:35–40.
 36. Mamula P, Telega GW, Markowitz JE, et al. Inflammatory bowel disease in children 5 years of age and younger. *Am J Gastroenterol* 2002;97:2005–2010.
 37. Aloï M, Lionetti P, Barabino A, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2014;20:597–605.
 38. Hsieh KH, Chang MH, Lee CY, Wang CY. Wiskott-Aldrich syndrome and inflammatory bowel disease. *Ann Allergy* 1988;60:429–431.
 39. Marks DJ, Seymour CR, Sewell GW, et al. Inflammatory bowel diseases in patients with adaptive and complement immunodeficiency disorders. *Inflamm Bowel Dis* 2010;16:1984–1992.
 40. Alangari A, Alsultan A, Adly N, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. *J Allergy Clin Immunol* 2012;130:481–488.e2.
 41. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. *Blood* 2014;124: 2337–2344.
 42. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. *N Engl J Med* 2009;361:2046–2055.
 43. Randall KL, Lambe T, Johnson AL, et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. *Nat Immunol* 2009;10:1283–1291.
 44. Brooks EG, Filipovich AH, Padgett JW, et al. T-cell receptor analysis in Omenn's syndrome: evidence for defects in gene rearrangement and assembly. *Blood* 1999;93:242–250.
 45. Kato M, Kimura H, Seki M, et al. Omenn syndrome—review of several phenotypes of Omenn syndrome and RAG1/RAG2 mutations in Japan. *Allergol Int* 2006; 55:115–119.
 46. Schuetz C, Huck K, Gudowius S, et al. An immunodeficiency disease with RAG mutations and granulomas. *N Engl J Med* 2008;358:2030–2038.
 47. Washington K, Stenzel TT, Buckley RH, et al. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. *Am J Surg Pathol* 1996;20:1240–1252.
 48. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. *Am J Gastroenterol* 2010;105:2262–2275.
 49. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. *Clin Immunol* 1999;92:34–48.
 50. van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. *N Engl J Med* 2006;354:1901–1912.
 51. Zonana J, Elder ME, Schneider LC, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). *Am J Hum Genet* 2000;67:1555–1562.
 52. Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. *Am J Gastroenterol* 2009; 104:117–124.
 53. Patey-Mariaud de Serre N, Canioni D, Ganousse S, et al. Digestive histopathological presentation of IPEX syndrome. *Mod Pathol* 2009;22:95–102.
 54. Levy M, Arion A, Berrebi D, et al. Severe early-onset colitis revealing mevalonate kinase deficiency. *Pediatrics* 2013;132:e779–e783.
 55. Demir A, Akyuz F, Gokturk S, et al. Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening. *Scand J Gastroenterol* 2014;49:1414–1418.
 56. Gurkan OE, Yilmaz G, Aksu AU, et al. Colonic lymphoid nodular hyperplasia in childhood: causes of familial Mediterranean fever need extra attention. *J Pediatr Gastroenterol Nutr* 2013;57:817–821.
 57. Chalaris A, Gewiese J, Paliga K, et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. *Biochim Biophys Acta* 2010; 1803:234–245.
 58. Blaydon DC, Biancheri P, Di WL, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. *N Engl J Med* 2011;365:1502–1508.
 59. Karamchandani-Patel G, Hanson EP, Saltzman R, et al. Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels. *Ann Allergy Asthma Immunol* 2011;107:50–56.
 60. Zimmer KP, Schumann H, Mecklenbeck S, Bruckner-Tuderman L. Esophageal stenosis in childhood: dystrophic epidermolysis bullosa without skin blistering due to collagen VII mutations. *Gastroenterology* 2002;122: 220–225.
 61. Sadler E, Klausegger A, Muss W, et al. Novel KIND1 gene mutation in Kindler syndrome with severe gastrointestinal tract involvement. *Arch Dermatol* 2006;142:1619–1624.
 62. Ussar S, Moser M, Widmaier M, et al. Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. *PLoS Genet* 2008;4:e1000289.
 63. Kern JS, Herz C, Haan E, et al. Chronic colitis due to an epithelial barrier defect: the role of kindlin-1 isoforms. *J Pathol* 2007;213:462–470.
 64. Fiskerstrand T, Arshad N, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. *N Engl J Med* 2012;366:1586–1595.
 65. Chalaris A, Adam N, Sina C, et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. *J Exp Med* 2010; 207:1617–1624.
 66. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. *Nature* 2007;446:557–561.

67. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. *Nature* 2007;446:552–556.
68. Cheng LE, Kanwar B, Tcheurekdjian H, et al. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. *Clin Immunol* 2009;132:124–131.
69. Luetkeke NC, Qiu TH, Peiffer RL, et al. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. *Cell* 1993;73:263–278.
70. Mann GB, Fowler KJ, Gabriel A, et al. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. *Cell* 1993;73:249–261.
71. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. *Annu Rev Immunol* 2002;20:495–549.
72. Hand TW, Dos Santos LM, Bouladoux N, et al. Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. *Science* 2012;337:1553–1556.
73. Cong Y, Feng T, Fujihashi K, et al. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. *Proc Natl Acad Sci USA* 2009;106:19256–19261.
74. Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. *Cell* 1992;68:869–877.
75. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. *Cell* 1992;68:855–867.
76. Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. *J Exp Med* 1994;180:1955–1960.
77. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. *J Allergy Clin Immunol* 2013;131:959–971.
78. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. *Nature* 1993;361:226–233.
79. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). *Clin Immunol* 1999;93:190–197.
80. Pai SY, Cowan MJ. Stem cell transplantation for primary immunodeficiency diseases: the North American experience. *Curr Opin Allergy Clin Immunol* 2014;14:521–526.
81. Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. *J Allergy Clin Immunol* 2014;133:1092–1098.
82. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T-B⁺NK⁺ severe combined immunodeficiency. *Nat Genet* 1998;20:394–397.
83. Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. *N Engl J Med* 2003;349:1821–1828.
84. Nielsen C, Jakobsen MA, Larsen MJ, et al. Immunodeficiency associated with a nonsense mutation of IKBKB. *J Clin Immunol* 2014;34:916–921.
85. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. 1994;78:635–644.
86. Watanabe Y, Sasahara Y, Ramesh N, et al. T-cell receptor ligation causes Wiskott-Aldrich syndrome protein degradation and F-actin assembly downregulation. *J Allergy Clin Immunol* 2013;132:648–655.e1.
87. Shimizu M, Kanegane H, Wada T, et al. Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. *J Allergy Clin Immunol* 2013;131:587–590, e1–3.
88. Westerberg LS, Dahlberg C, Baptista M, et al. Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B-cell development and function. *Blood* 2012;119:3966–3974.
89. Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. *J Exp Med* 2011;208:2033–2042.
90. Lanzi G, Moratto D, Vairo D, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. *J Exp Med* 2012;209:29–34.
91. Nguyen DD, Maillard MH, Cotta-de-Almeida V, et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. *Gastroenterology* 2007;133:1188–1197.
92. Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4⁺CD25⁺Foxp3⁺ regulatory T cells. *J Exp Med* 2007;204:381–391.
93. Nguyen DD, Wurbel MA, Goettel JA, et al. Wiskott-Aldrich syndrome protein deficiency in innate immune cells leads to mucosal immune dysregulation and colitis in mice. *Gastroenterology* 2012;143:719–729, e1–2.
94. van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. *Clin Dev Immunol* 2007;2007:89017.
95. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. *J Allergy Clin Immunol* 2007;120:744–750.
96. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity. *Front Immunol* 2012;3:211.
97. Zeissig S, Petersen BS, Tomczak M, et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. *Gut* 2014, Published online. <http://dx.doi.org/10.1136/gutjnl-2014-308541>.
98. Cebula A, Seweryn M, Rempala GA, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. *Nature* 2013;497:258–262.
99. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. *Annu Rev Immunol* 2012;30:531–564.
100. Lathrop SK, Bloom SM, Rao SM, et al. Peripheral education of the immune system by colonic commensal microbiota. *Nature* 2011;478:250–254.

101. Chinen T, Volchkov PY, Chervonsky AV, et al. A critical role for regulatory T cell-mediated control of inflammation in the absence of commensal microbiota. *J Exp Med* 2010;207:2323–2330.
102. Schultz M, Tonkonogy SL, Sellon RK, et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. *Am J Physiol* 1999; 276:G1461–G1472.
103. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature* 2014;513:564–568.
104. Shim JO, Hwang S, Yang HR, et al. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis. *Eur J Gastroenterol Hepatol* 2013;25:1235–1240.
105. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* 2001;19:683–765.
106. Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. *Brief Funct Genomics* 2013;12:489–498.
107. Engelhardt KR, Grimbacher B. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. *Curr Top Microbiol Immunol* 2014; 380:1–18.
108. Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. *Proc Natl Acad Sci USA* 2005; 102:8686–8691.
109. Neven B, Mamessier E, Bruneau J, et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. *Blood* 2013;122:3713–3722.
110. Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. *J Allergy Clin Immunol* 2013;131:825–830.
111. Murugan D, Albert MH, Langemeier J, et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. *J Clin Immunol* 2014;34:331–339.
112. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 1993; 75:263–274.
113. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect Immun* 1998; 66:5224–5231.
114. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity* 2008;28:546–558.
115. Roers A, Siewe L, Strittmatter E, et al. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. *J Exp Med* 2004; 200:1289–1297.
116. Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. *Immunity* 2014;40:706–719.
117. Zigmund E, Bernshtein B, Friedlander G, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. *Immunity* 2014;40:720–733.
118. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat Immunol* 2011; 12:383–390.
119. Sonnenberg GF, Artis D. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. *Immunity* 2012;37:601–610.
120. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells—a proposal for uniform nomenclature. *Nat Rev Immunol* 2013;13:145–149.
121. Sonnenberg GF, Monticelli LA, Alenghat T, et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. *Science* 2012; 336:1321–1325.
122. Hepworth MR, Monticelli LA, Fung TC, et al. Innate lymphoid cells regulate CD4⁺ T-cell responses to intestinal commensal bacteria. *Nature* 2013;498:113–117.
123. Bernink JH, Peters CP, Munneke M, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. *Nat Immunol* 2013;14:221–229.
124. Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. *J Exp Med* 2011; 208:1127–1133.
125. Takayama T, Kamada N, Chinen H, et al. Imbalance of NKp44⁺NKp46⁻ and NKp44⁻NKp46⁺ natural killer cells in the intestinal mucosa of patients with Crohn's disease. *Gastroenterology* 2010;139:882–892, e1–3.
126. Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-22 and interleukin-22-producing NKp44⁺ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. *Arthritis Rheum* 2012;64:1869–1878.
127. Fuchs A, Vermi W, Lee JS, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. *Immunity* 2013;38:769–781.
128. Hepworth MR, Fung TC, Masur SH, et al. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells. *Science* 2015;348:1031–1035.
129. Kang EM, Marciano BE, DeRavin S, et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. *J Allergy Clin Immunol* 2011; 127:1319–1326.
130. Abo A, Pick E, Hall A, et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. *Nature* 1991;353:668–670.
131. Matute JD, Arias AA, Wright NA, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. *Blood* 2009;114:3309–3315.
132. Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom

- and Ireland: a comprehensive national patient-based registry. *Clin Exp Immunol* 2008;152:211–218.
133. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). *J Clin Immunol* 2008;28(Suppl 1):S67–S72.
 134. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. *J Clin Invest* 1998;102:2146–2155.
 135. Muise AM, Xu W, Guo CH, et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. *Gut* 2012;61:1028–1035.
 136. Dhillon SS, Fattouh R, Elkadri A, et al. Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. *Gastroenterology* 2014;147:680–689.e2.
 137. Roos D, Law SK. Hematologically important mutations: leukocyte adhesion deficiency. *Blood Cells Mol Dis* 2001;27:1000–1004.
 138. van de Vijver E, Maddalena A, Sanal O, et al. Hematologically important mutations: leukocyte adhesion deficiency (first update). *Blood Cells Mol Dis* 2012;48:53–61.
 139. Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. *Mol Immunol* 2013;55:49–58.
 140. Davis MK, Rufo PA, Polyak SF, et al. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. *J Inherit Metab Dis* 2008;31(Suppl 3):505–509.
 141. Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. *Clin Infect Dis* 2010;51:1429–1434.
 142. Kato K, Kojima Y, Kobayashi C, et al. Successful allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease with inflammatory complications and severe infection. *Int J Hematol* 2011;94:479–482.
 143. de Luca A, Smeekens SP, Casagrande A, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. *Proc Natl Acad Sci USA* 2014;111:3526–3531.
 144. Bianco AM, Girardelli M, Vozzi D, et al. Mevalonate kinase deficiency and IBD: shared genetic background. *Gut* 2014;63:1367–1368.
 145. Kuloglu Z, Kansu A, Ustundag G, et al. An infant with severe refractory Crohn's disease and homozygous MEFV mutation who dramatically responded to colchicine. *Rheumatol Int* 2012;32:783–785.
 146. Beser OF, Kasapcopur O, Cokugras FC, et al. Association of inflammatory bowel disease with familial Mediterranean fever in Turkish children. *J Pediatr Gastroenterol Nutr* 2013;56:498–502.
 147. Mora AJ, Wolfsohn DM. The management of gastrointestinal disease in Hermansky-Pudlak syndrome. *J Clin Gastroenterol* 2011;45:700–702.
 148. Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. *Clin Immunol* 2013;147:155–174.
 149. Speckmann C, Lehmborg K, Albert MH, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. *Clin Immunol* 2013;149:133–141.
 150. Latour S, Aguilar C. XIAP deficiency syndrome in humans. *Semin Cell Dev Biol* 2015;39:115–123.
 151. Pedersen J, LaCasse EC, Seidelin JB, et al. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. *Trends Mol Med* 2014;20:652–665.
 152. Aguilar C, Latour S. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. *J Clin Immunol* 2015;35:331–338.
 153. Filipovich AH. The expanding spectrum of hemophagocytic lymphohistiocytosis. *Curr Opin Allergy Clin Immunol* 2011;11:512–516.

Received March 9, 2015. Accepted June 21, 2015.

Correspondence

Address correspondence to: Gregory F. Sonnenberg, PhD, Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, 413 East 69th Street, Belfer Research Building 512, Box 190, New York, NY 10021. e-mail: gfsonnenberg@med.cornell.edu; or Judith R. Kelsen, MD, 7NW, Division of Pediatric Gastroenterology, 3400 Civic Center Boulevard, The Children's Hospital of Philadelphia, Philadelphia, PA 19104. Fax: (215) 590-5326.

Conflicts of interest

The authors disclose no conflicts.

Funding

This study was funded by the National Institutes of Health (K23DK100461–01A1) (to J.R.K.); the National Institutes of Health (DP5OD012116 and R56AI114724), the NIAID Mucosal Immunology Studies Team (MIST) Scholar Award in Mucosal Immunity and the Institute for Translational Medicine, and the Therapeutics Transdisciplinary Program in Translational Medicine and Therapeutics (UL1-RR024134 from the US National Center for Research Resources) (to G.F.S. laboratory); the National Institutes of Health (AI061570, AI074878, AI095466, AI095608, AI102942, AI097333 and AI106697), the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award, and the Crohn's and Colitis Foundation of America (to D.A. laboratory).